Loading...
Hypertriglyceridemia is very common in clinical practice. Unfortunately, currently available therapies provide only modest reduction of triglyceride levels. One non–FDA-approved agent currently under investigation, olezarsen, is an antisense oligonucleotide that targets mRNA on the gene encoding apolipoprotein C-III, a lipoprotein that increases plasma triglyceride levels.
In the industry-funded, phase 2B, Bridge-TIMI 73a trial (NCT05355402), 154 adults with moderate hypertriglyceridemia (fasting triglyceride, 150–499 mg/dl) plus elevated cardiovascular risk or with severe hypertriglyceridemia (fasting triglyceride, ≥500 mg/dl) were randomly assigned to receive 50 or 80 mg of olezarsen subcutaneously once per month for 12 months; within each…